Sarcoma vaccine - MabVax/Memorial Sloan-Kettering Cancer Center

Drug Profile

Sarcoma vaccine - MabVax/Memorial Sloan-Kettering Cancer Center

Alternative Names: MV-Sarc; Trivalent ganglioside vaccine

Latest Information Update: 26 Apr 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Memorial Sloan-Kettering Cancer Center
  • Developer MabVax Therapeutics; Memorial Sloan-Kettering Cancer Center
  • Class Cancer vaccines; Conjugate-vaccines; Monoclonal antibodies; Vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Sarcoma

Most Recent Events

  • 10 Mar 2017 MabVax Therapeutics completes a phase II trial in Sarcoma in USA (SC) (NCT01141491)
  • 07 Apr 2015 Phase II development is ongoing in USA
  • 08 Jul 2014 MabVax Therapeutics merged with a wholly-owned subsidiary of Telik
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top